SK12872003A3 - Nádorové signálne znaky rakovinového nádoru obličkovej bunky - Google Patents

Nádorové signálne znaky rakovinového nádoru obličkovej bunky Download PDF

Info

Publication number
SK12872003A3
SK12872003A3 SK1287-2003A SK12872003A SK12872003A3 SK 12872003 A3 SK12872003 A3 SK 12872003A3 SK 12872003 A SK12872003 A SK 12872003A SK 12872003 A3 SK12872003 A3 SK 12872003A3
Authority
SK
Slovakia
Prior art keywords
antibody
rcc
tumor
protein
tumor marker
Prior art date
Application number
SK1287-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Roland Kellner
Siegfried Matzku
Barbara Seliger
Rudolf Lichtenfels
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK12872003A3 publication Critical patent/SK12872003A3/sk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK1287-2003A 2001-04-03 2002-03-28 Nádorové signálne znaky rakovinového nádoru obličkovej bunky SK12872003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01108385 2001-04-03
PCT/EP2002/003503 WO2002082076A2 (en) 2001-04-03 2002-03-28 Renal cell carcinoma tumor markers

Publications (1)

Publication Number Publication Date
SK12872003A3 true SK12872003A3 (sk) 2004-02-03

Family

ID=8177036

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1287-2003A SK12872003A3 (sk) 2001-04-03 2002-03-28 Nádorové signálne znaky rakovinového nádoru obličkovej bunky

Country Status (15)

Country Link
US (1) US20040096916A1 (pt)
EP (1) EP1373900A2 (pt)
JP (1) JP2004531713A (pt)
KR (1) KR20030086345A (pt)
CN (1) CN1630819A (pt)
BR (1) BR0208603A (pt)
CA (1) CA2442957A1 (pt)
CZ (1) CZ20032787A3 (pt)
HU (1) HUP0303749A3 (pt)
MX (1) MXPA03009018A (pt)
PL (1) PL363009A1 (pt)
RU (1) RU2003130645A (pt)
SK (1) SK12872003A3 (pt)
WO (1) WO2002082076A2 (pt)
ZA (1) ZA200308487B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252821B2 (en) * 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7413851B2 (en) 2002-12-13 2008-08-19 Aurelium Biopharma, Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
EP1588162B1 (en) 2003-01-03 2008-09-17 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004080819A2 (en) * 2003-03-14 2004-09-23 Aurelium Biopharma Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US20050026224A1 (en) * 2003-04-28 2005-02-03 Follettie Maximillian T. Methods and compositions for modulating G-protein coupled receptor 54
GB2402212B (en) * 2003-05-28 2007-04-11 Univ Chang Gung Detecting recurrence and high stage bladder carcinoma
PL1720611T3 (pl) * 2004-02-16 2010-09-30 Proteosys Ag Marker diagnostyczny dla raka
CN1712542B (zh) * 2004-06-25 2012-07-04 中国科学院上海生命科学研究院 肝细胞癌相关的蛋白质分子标记原癌蛋白18的筛选及其应用
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20060148674A1 (en) * 2004-12-31 2006-07-06 Luduena Richard F Therapeutic composition
WO2006083986A2 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
EP1724586A3 (en) * 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
JP2007033041A (ja) * 2005-07-22 2007-02-08 Sumitomo Chemical Co Ltd 胎盤型グルタチオン−ｓ−トランスフェラ−ゼ酵素を認識する抗体に対して陰性を示すラット肝臓腫瘍性病変又は前腫瘍性病変の検定方法
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
US20100152055A1 (en) * 2005-09-02 2010-06-17 Satoko Kozono Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
AU2006321027A1 (en) * 2005-11-29 2007-06-07 Denator Aktiebolag Method for determining the quality of a biological sample
JP5211315B2 (ja) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
WO2008032868A1 (fr) 2006-09-15 2008-03-20 Shimadzu Corporation Marqueur tumoral du cancer du rein, et méthode de détermination de la survenue du cancer du rein
AU2008307145B2 (en) * 2007-10-04 2014-07-10 Bionomics Limited Markers of endothelial cells and uses thereof
DE102008011850A1 (de) * 2008-02-29 2009-09-03 Michael Grzendowski Biomarker für die Diagnose von Hirntumor
CN101290321A (zh) * 2008-04-11 2008-10-22 中国医学科学院肿瘤研究所 膜联蛋白a2的血清检测方法、检测试剂盒及其应用
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
ES2619805T3 (es) * 2011-01-21 2017-06-27 Basilea Pharmaceutica Ag Uso de estatmina como un biomarcador de la respuesta de fármacos a furazanobenzimidazoles
CN102288470A (zh) * 2011-07-20 2011-12-21 中国热带农业科学院热带生物技术研究所 一种考马斯亮蓝g250染色方法及其专用染色液和应用
CN102375061B (zh) * 2011-09-20 2014-07-30 国家人口计生委科学技术研究所 一种检测前列腺癌的elisa试剂盒
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
CN104718455B (zh) * 2012-09-07 2017-03-08 基诺麦因有限公司 肾癌血液生物标志物(Biomarker)的检测方法及试剂盒
CN117660296A (zh) 2012-10-24 2024-03-08 普罗基德尼 肾细胞群及其用途
EP2735874A1 (en) * 2012-11-21 2014-05-28 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer
SE538211C2 (sv) * 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
CN104330570B (zh) * 2014-10-11 2016-03-16 中国科学院微生物研究所 人热休克蛋白gp96在制备筛查肝病的产品中的应用
WO2017134668A1 (en) 2016-02-04 2017-08-10 Immune System Key Ltd. Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
CN106526185B (zh) * 2016-10-28 2018-03-30 拜尔康(天津)医药科技有限公司 用于检测去势抵抗性前列腺癌的elisa试剂盒及检测方法
MX2019006866A (es) * 2016-12-16 2019-08-22 Merck Patent Gmbh Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.
CN113447656B (zh) * 2021-07-01 2022-05-13 浙江大学 检测抗丝状肌动蛋白成帽蛋白β-IgG抗体的试剂盒
CN114099639B (zh) * 2021-11-25 2024-03-01 徐州医科大学 H1-pHSP65纳米疫苗及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972626A (en) * 1997-07-30 1999-10-26 University Of Massachusetts Cancer detection by centrosome abnormality

Also Published As

Publication number Publication date
HUP0303749A3 (en) 2005-09-28
ZA200308487B (en) 2005-01-31
EP1373900A2 (en) 2004-01-02
PL363009A1 (en) 2004-11-15
KR20030086345A (ko) 2003-11-07
JP2004531713A (ja) 2004-10-14
CN1630819A (zh) 2005-06-22
WO2002082076A3 (en) 2003-09-04
HUP0303749A2 (hu) 2004-03-01
CA2442957A1 (en) 2002-10-17
CZ20032787A3 (en) 2004-03-17
US20040096916A1 (en) 2004-05-20
WO2002082076A2 (en) 2002-10-17
BR0208603A (pt) 2004-03-02
RU2003130645A (ru) 2005-04-10
MXPA03009018A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
SK12872003A3 (sk) Nádorové signálne znaky rakovinového nádoru obličkovej bunky
US20210145700A1 (en) Genetic products differentially expressed in tumors and the use thereof
AU2010202440B2 (en) Genetic products differentially expressed in tumors and the use thereof
CA2879185C (en) Method for detecting cancer
JP6886816B2 (ja) 免疫系調節薬
US20210269549A1 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
CA2879304A1 (en) Method for detecting cancer
US20090221004A1 (en) Caspase-cleavage anti-keratin antibodies for detection of apoptosis
KR101458483B1 (ko) 신장암 진단 조성물 및 키트
EP3656794A1 (en) Composition and methods for detecting cancer
US20080219981A1 (en) Diagnostic Kit for Solid Cancer and Medicament for Solid Cancer Therapy
JPWO2009044561A1 (ja) 抗ｐｒｏＮＴ／ＮＭＮモノクローナル抗体
US20080305499A1 (en) Anti-Synoviolin Antibody
JPH0816679B2 (ja) 体液および組織におけるｒａｓタンパクの検出、定量および分類
US20170313770A1 (en) Reagents for detecting or diagnosing cancer cells having high invasive capacity
WO2022080305A1 (ja) 抗ｐｔｄｓｓ２抗体
JP6729917B2 (ja) ＥｐｈＡ２ Ｎ末端フラグメント抗体
JPWO2003084991A1 (ja) アトピー性皮膚炎誘引蛋白質
AU2002308206A1 (en) Renal cell carcinoma tumor markers
AU2016203425B2 (en) Genetic products differentially expressed in tumors and the use thereof
AU2013260709B2 (en) Genetic products differentially expressed in tumors and the use thereof
JP4395004B2 (ja) 胚細胞腫瘍の検出方法
EP2527361B1 (en) Biomarkers for in vitro prognosis and diagnosis of graft and transplant rejection
AU2011256897B2 (en) Genetic products differentially expressed in tumors and the use thereof
KR20120060049A (ko) 비만 바이오마커 검출용 조성물 및 키트